Novartis Gene Therapies
2275 Half Day Road, Suite 200
About Novartis Gene Therapies
Since 2013, Novartis Gene Therapies (formerly AveXis) has had one focus: bringing change to those devastated by genetic diseases.
The Novartis Gene Therapies culture embraces this mission. As a compassionate and dedicated team, we are enthusiastic about the science behind our work and finding answers to difficult questions. We are dedicated to communities affected by rare diseases, and these patients and families are the motivation for everything we do.
We have built a team with exceptional depth of experience, unified by a common vision; to develop gene therapies with the potential to positively impact the lives of the patients and families devastated by rare and life-threatening neurological genetic diseases. Though we are proud of what we have achieved to date, we remain relentlessly focused on making that vision a reality.
With cutting-edge technology, we are making progress in the treatment of rare and life-threatening neurological genetic diseases. Our initial gene therapy for spinal muscular atrophy (SMA) has been approved in the U.S., Japan, EU and Brazil.
We are headquartered in Bannockburn, IL with another location in Deerfield, IL. Our manufacturing facilities are located in Libertyville, IL, Durham, NC and Longmont, CO. Our research site is located in San Diego, CA. The European headquarters is located in Zurich, Switzerland and Novartis Pharma K.K. (“Novartis Pharma”) is located in Tokyo, Japan.
Stock Symbol: NVS
Stock Exchange: NYSE
96 articles with Novartis Gene Therapies
As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
According to a BioSpace survey, almost 70% of respondents are likely to look for a new job in the 12 months. The question is, why? Of those planning to look for a new job, 54% said they wanted new challenges and 42% said they wanted more rewarding opportunities. How about you? Are you ready to lo...
AveXis, a Novartis company, announced innovative access programs for Zolgensma® for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy with bi-allelic mutations in the survival motor neuron 1 gene.
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
AveXis, a Novartis company, announced the US Food and Drug Administration has approved Zolgensma® for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy with bi-allelic mutations in the survival motor neuron 1 gene.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
AveXis, a Novartis company, today announced interim long-term follow-up data from the Phase 1 START trial of the investigational product Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)1 that showed durability of the gene therapy in patients with spinal muscular atrophy (SMA) Type 1 nearly four years after treatment.
5/6/2019SMA is a severe neuromuscular disease caused by a mutation in the SMN1 gene, which codes for SMN, a protein necessary for motor neuron function.
Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
Interim data reported for the first time from SPR1NT in pre-symptomatic SMA showed age-appropriate motor milestone achievement
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don't stop looking. You never know what may come your way!
Just as Novartis and AveXis’ gene therapy, Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy (SMA) is progressing toward approval, a second patient death was reported.
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
AveXis, a Novartis company, announced interim data from its Phase III STR1VE clinical trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
• Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial • First-in-human biodistribution data show transduction in intended CNS targets and widespread SMN expression comparable to tissue from unaffected control • More than 150 patients treated with Zolgensma, only 5% of screened patients up to 5 years old excluded due to AAV9 antibody titers greater than 1:50
The Novartis subsidiary said it plans to offer jobs to the 150 employees currently working at the Colorado facility and add additional headcount there in the future.
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy
Anchored by Raleigh, Durham and the Research Triangle Park region, BioSpace’s Bio NC Hotbed is one of the faster-growing areas for biopharma in the U.S.
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
According to a recent BioSpace survey, 70% of life science employers indicated their company anticipates an increase in the number of open positions during 2019. So if you are on the job hunt, keep your eye out for new positions posted throughout the year!